Literature DB >> 7494267

Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus.

A McGoldrick1, A J Macadam, G Dunn, A Rowe, J Burlison, P D Minor, J Meredith, D J Evans, J W Almond.   

Abstract

Of the 55 point mutations which distinguish the type 1 poliovirus vaccine strain (Sabin 1) from its neurovirulent progenitor (P1/Mahoney), two have been strongly implicated by previous studies as determinants of the attenuation phenotype. A change of an A to a G at position 480, located within the 5' noncoding region, has been suggested to be the major attenuating mutation, analogous to the mutations at positions 481 and 472 in poliovirus types 2 and 3, respectively. In addition, the change of a U to a C at position 6203, resulting in an amino acid change in the polymerase protein 3D, has also been implicated as a determinant of attenuation, albeit to a lesser extent. To assess the contributions of these mutations to attenuation and temperature sensitivity, reciprocal changes were generated at these positions in infectious cDNA clones of Sabin 1 and P1/Mahoney. Assays in tissue culture and primates indicated that the two mutations make some contribution to the temperature sensitivity of the Sabin 1 strain but that neither is a strong determinant of attenuation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494267      PMCID: PMC189699     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines.

Authors:  J E SALK; U KRECH; J S YOUNGNER; B L BENNETT; L J LEWIS; P L BAZELEY
Journal:  Am J Public Health Nations Health       Date:  1954-05

2.  Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis.

Authors:  A B Sabin
Journal:  JAMA       Date:  1965-11-22       Impact factor: 56.272

3.  Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.

Authors:  M J Bouchard; D H Lam; V R Racaniello
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

4.  Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis.

Authors:  M Furione; S Guillot; D Otelea; J Balanant; A Candrea; R Crainic
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

5.  Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses.

Authors:  D Otelea; S Guillot; M Furione; A A Combiescu; J Balanant; A Candrea; R Crainic
Journal:  Dev Biol Stand       Date:  1993

6.  Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.

Authors:  G V Rezapkin; K M Chumakov; Z Lu; Y Ran; E M Dragunsky; I S Levenbook
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

7.  Cloned poliovirus complementary DNA is infectious in mammalian cells.

Authors:  V R Racaniello; D Baltimore
Journal:  Science       Date:  1981-11-20       Impact factor: 47.728

8.  Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.

Authors:  A J Macadam; S R Pollard; G Ferguson; R Skuce; D Wood; J W Almond; P D Minor
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

9.  Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence.

Authors:  H Horie; S Koike; T Kurata; Y Sato-Yoshida; I Ise; Y Ota; S Abe; K Hioki; H Kato; C Taya
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.

Authors:  A Nomoto; T Omata; H Toyoda; S Kuge; H Horie; Y Kataoka; Y Genba; Y Nakano; N Imura
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  30 in total

1.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

7.  A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China.

Authors:  Yongjuan Liu; Chong Fu; Suying Wu; Xiong Chen; Yingying Shi; Bingfei Zhou; Lianglu Zhang; Fengfeng Zhang; Zhihao Wang; Yingying Zhang; Chengpeng Fan; Song Han; Jun Yin; Biwen Peng; Wanhong Liu; Xiaohua He
Journal:  Virus Genes       Date:  2014-01-19       Impact factor: 2.332

8.  Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.

Authors:  Andrew J Macadam; Geraldine Ferguson; David M Stone; Janet Meredith; Sarah Knowlson; Ghazi Auda; Jeffrey W Almond; Philip D Minor
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

9.  Phylogenetic analysis reveals a correlation between the expansion of very virulent infectious bursal disease virus and reassortment of its genome segment B.

Authors:  Chung-Chau Hon; Tsan-Yuk Lam; Alexei Drummond; Andrew Rambaut; Yiu-Fai Lee; Chi-Wai Yip; Fanya Zeng; Pui-Yi Lam; Patrick T W Ng; Frederick C C Leung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

10.  Growth kinetic analysis of bi-recombinant poliovirus vaccine strains.

Authors:  Vaia Pliaka; Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Georgia Papadi; Dimitris Tsakogiannis; Anastassia Pratti; Stamatina Levidiotou-Stefanou; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2010-01-21       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.